KN026 combination

DRUG2 trials

Sponsors

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Conditions

HER2-positive Solid TumorsMetastatic Breast Cancer

Phase 2

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., LtdMetastatic Breast Cancer

Start: 2019-12-31End: 2025-12-31Updated: 2023-09-21

Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

CompletedNCT04521179

Jiangsu Alphamab Biopharmaceuticals Co., LtdHER2-positive Solid Tumors

Start: 2020-12-07End: 2023-05-22Updated: 2023-09-21

Related Papers

Longitudinal tissue analysis reveals microenvironmental changes correlate with combined immunotherapy and targeted therapy response in metastatic breast cancer.

2025-10-05

Longitudinal tissue analysis and correlation of microenvironmental changes with combined immunotherapy and targeted therapy response in metastatic breast cancer.

Journal of Clinical Oncology2025-05-28

Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.

Journal of Clinical Oncology2023-06-016 citations

Abstract P5-02-34: Single-cell Analysis of KN026 in Combination with KN046 in Treating Patients with Advanced HER2-positive Breast Cancer

Cancer Research2023-03-011 citations

Abstract CT542: Preliminary safety and efficacy results of KN046 in combination with KN026 in patients with locally advanced unresectable or metastatic HER2-positive solid cancer

Cancer Research2022-06-153 citations

Abstract P5-16-04: Preliminary safety and efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with KN026 (a HER2-targeted bispecific antibody) in patients with metastatic HER2-positive breast cancer: A phase II trial

Cancer Research2022-02-154 citations